MentionFox
Home › Stakes › Mentari Therapeutics, Inc.
5%+ stakes · Schedule 13D and 13G

Mentari Therapeutics, Inc.: 5%+ holders

Before you sign with, sell to or invest in Mentari Therapeutics, Inc.

MentionFox check on Mentari Therapeutics, Inc.: no red flags found in 10 sources; 1 item to note (checked 16 November 2026). mentionfox.com/c/stakes/mentari-therapeutics

  • Note: Layoff plan disclosed Mar 2026 (filing)

Check Mentari Therapeutics, Inc. before you sign, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Mentari Therapeutics, Inc.?

Who has reported owning 5% or more of Mentari Therapeutics, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

As of November 16, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Mentari Therapeutics, Inc. The largest reported stake is Vivo Opportunity Fund Holdings, L.P.'s, at 21.7%. 9 filings are on record since January 20, 2026 (Schedule 13D, June 10, 2026).

Fairmount Funds Management LLC also filed stake reports on 14 other companies ↓

Sell to companies like Mentari Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 2,977,478 · Sole dispositive: 0 · Shared dispositive: 2,977,478 · SCHEDULE 13G, 2026-11-13
  • · Reporting person: Commodore Capital LP · Sole voting: 0 · Shared voting: 2,977,630 · Sole dispositive: 0 · Shared dispositive: 2,977,630 · SCHEDULE 13G, 2026-11-13
  • · Reporting person: Fairmount Funds Management LLC · Sole voting: 0 · Shared voting: 10,555,507 · Sole dispositive: 0 · Shared dispositive: 10,555,507 · SCHEDULE 13D, 2026-11-12
  • · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 943,668 · Sole dispositive: 0 · Shared dispositive: 943,668 · SCHEDULE 13G/A, 2026-10-07
  • · Reporting person: Ikarian Capital, LLC · Sole voting: 0 · Shared voting: 137,634 · Sole dispositive: 0 · Shared dispositive: 137,634 · SCHEDULE 13G, 2026-08-14
At 5% or more7
Filings9
Latest filing2026-11-13

Mentari Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2026-01-20. 7 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: 1 filing or notice, latest 2026-03-06 (layoff filings and notices).

Holders

HolderPercentSharesLatestEvent date
Vivo Opportunity Fund Holdings, L.P.21.7%718,444SCHEDULE 13D, 2026-06-102026-05-19
Fairmount Funds Management LLC19.99%10,555,507SCHEDULE 13D, 2026-11-122026-11-06
ADAR1 Capital Management, LLC17.2%943,668SCHEDULE 13G/A, 2026-10-072026-09-30
Sabby Management, LLC9.9%280,138SCHEDULE 13G, 2026-01-202025-12-31
Squadron Master Fund LP9.8%325,000SCHEDULE 13G, 2026-05-272026-05-19
Deep Track Capital, LP5.64%2,977,478SCHEDULE 13G, 2026-11-132026-11-06
Commodore Capital LP5.6%2,977,630SCHEDULE 13G, 2026-11-132026-11-06
Ikarian Capital, LLC4.2%137,634SCHEDULE 13G, 2026-08-142026-06-30

Holding shares or following this stake? See who's behind Mentari Therapeutics, Inc. and the warning signs.

Free to see. No signup.

Keep reading

More on Mentari Therapeutics, Inc. and the records around it.

Mentari Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Mentari Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Mentari Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Mentari Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    11 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vivo Opportunity Fund Holdings, L.P.718,4440718,4440SCHEDULE 13D, 2026-06-10
Vivo Opportunity, LLC718,4440718,4440SCHEDULE 13D, 2026-06-10
Vivo Opportunity Cayman Fund, L.P.72,535072,5350SCHEDULE 13D, 2026-06-10
Vivo Opportunity Cayman, LLC72,535072,5350SCHEDULE 13D, 2026-06-10
Fairmount Funds Management LLC010,555,507010,555,507SCHEDULE 13D, 2026-11-12
Fairmount Healthcare Fund II L.P.010,555,507010,555,507SCHEDULE 13D, 2026-11-12
Peter Evan Harwin010,555,507010,555,507SCHEDULE 13D, 2026-11-12
Tomas Kiselak010,555,507010,555,507SCHEDULE 13D, 2026-11-12
ADAR1 Capital Management, LLC0943,6680943,668SCHEDULE 13G/A, 2026-10-07
Daniel Schneeberger0943,6680943,668SCHEDULE 13G/A, 2026-10-07
Squadron Master Fund LP0325,0000325,000SCHEDULE 13G, 2026-05-27
Squadron Capital Management LLC0325,0000325,000SCHEDULE 13G, 2026-05-27
Matthew Sesterhenn0325,0000325,000SCHEDULE 13G, 2026-05-27
William Blank0325,0000325,000SCHEDULE 13G, 2026-05-27
Deep Track Capital, LP02,977,47802,977,478SCHEDULE 13G, 2026-11-13
Deep Track Biotechnology Master Fund, Ltd.02,214,13502,214,135SCHEDULE 13G, 2026-11-13
David Kroin02,977,47802,977,478SCHEDULE 13G, 2026-11-13
Deep Track Special Opportunities Fund, LP.0763,3430763,343SCHEDULE 13G, 2026-11-13
Commodore Capital LP02,977,63002,977,630SCHEDULE 13G, 2026-11-13
Commodore Capital Master LP02,977,63002,977,630SCHEDULE 13G, 2026-11-13
Robert Egen Atkinson02,977,63002,977,630SCHEDULE 13G, 2026-11-13
Michael Kramarz02,977,63002,977,630SCHEDULE 13G, 2026-11-13
Ikarian Capital, LLC0137,6340137,634SCHEDULE 13G, 2026-08-14
Neil Shahrestani0137,6340137,634SCHEDULE 13G, 2026-08-14

The latest filing identifies Mentari Therapeutics, Inc. by CUSIP 587157108 and gives its principal executive office as 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (SCHEDULE 13G, 2026-11-13).

Source of funds (Item 3)

The funds used to purchase the securities reported herein came from the working capital of Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P.Vivo Opportunity Fund Holdings, L.P., SCHEDULE 13D, 2026-06-10
In aggregate, the Reporting Persons have voting and dispositive power over 10,555,507 shares of Common Stock, which is comprised of (a) 10,555,507 shares of Common Stock directly held by Fund II, and exclude (b) 4,013,000 shares of Common Stock issuable upon conversion of 4,013 shares of Series A Preferred Stock directly held by Fund II and 1,468,222 shares of Common Stock issuable upon exercise of Pre-Funded Warrants directly held by Fund II.Fairmount Funds Management LLC, SCHEDULE 13D, 2026-11-12

Purpose of Transaction (Item 4)

Vivo Opportunity Fund Holdings, L.P.

On May 19, 2026, the Issuer, Indigo Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of the Issuer (the "First Merger Sub"), Indigo Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Issuer (the "Second Merger Sub" and, together with First Merger Sub, the "Merger Subs"), and Mentari Therapeutics, Inc., a Delaware corporation ("Mentari"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, (i) the First Merger Sub will merge with and into Mentari, with Mentari surviving the merger as a wholly owned subsidiary of the Company (the "First Merger"), and (ii) immediately following the First Merger and as part of the same overall transaction as the First Merger, Mentari will merge with and into the Second Merger Sub, with the Second Merger Sub surviving such merger (the "Second Merger" and, together with the First Merger, the "Merger"). Subject to the terms and conditions of the Merger Agreement, at the effective time of the First Merger (the "First Effective Time"), each share of Mentari capital stock outstanding immediately prior to the First Effective Time will be converted into the right to receive a number of the Issuer's common shares (the "Common Shares") equal to the exchange ratio determined under the Merger Agreement (the "Exchange …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-10; the filing has the rest

Fairmount Funds Management LLC

The Reporting Persons own 19.99% of the Company in the aggregate, based upon the Company's aggregate outstanding shares as of November 6, 2026. The Reporting Persons' securities include 10,555,507 shares of Common Stock directly held by Fund II, and exclude (i) 4,013,000 shares of Common Stock issuable upon conversion of 4,013 shares of Series A Preferred Stock directly held by Fund II and (ii) 1,468,222 shares of Common Stock issuable upon exercise of Pre-Funded Warrants directly held by Fund II. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 19.99% of the outstanding shares of Common Stock and the conversion of the Series A Preferred Stock is subject to a beneficial ownership limitation of 19.99% of the outstanding shares of Common Stock. The securities exclude shares of Common Stock issuable upon exercise of Pre-Funded Warrants and conversion of Series A Preferred Stock in excess of such beneficial ownership limitations. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the outstanding shares of Common Stock, the beneficial ownership limitation with respect to the Series A Preferred Stock will automatically reduce to 9.99%. Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, at any time and …The first part of Item 4 of the SCHEDULE 13D filed 2026-11-12; the filing has the rest

Timeline

FiledHolderPercentFiling
2026-01-20Sabby Management, LLC9.9%SCHEDULE 13G
2026-05-27Squadron Master Fund LP9.8%SCHEDULE 13G
2026-06-05ADAR1 Capital Management, LLC24.1%SCHEDULE 13G
2026-06-10Vivo Opportunity Fund Holdings, L.P.21.7%SCHEDULE 13D
2026-08-14Ikarian Capital, LLC4.2%SCHEDULE 13G
2026-10-07ADAR1 Capital Management, LLC17.2%SCHEDULE 13G/A
2026-11-12Fairmount Funds Management LLC19.99%SCHEDULE 13D
2026-11-13Deep Track Capital, LP5.64%SCHEDULE 13G
2026-11-13Commodore Capital LP5.6%SCHEDULE 13G

Questions about who owns Mentari Therapeutics, Inc.

Who owns Mentari Therapeutics, Inc.?

On this page, 7 holders' latest ownership filings report 5% or more of Mentari Therapeutics, Inc.: Vivo Opportunity Fund Holdings, L.P. (21.7%, Schedule 13D, filed 2026-06-10), Fairmount Funds Management LLC (19.99%, Schedule 13D, filed 2026-11-12), ADAR1 Capital Management, LLC (17.2%, Schedule 13G/A, filed 2026-10-07), Sabby Management, LLC (9.9%, Schedule 13G, filed 2026-01-20) and Squadron Master Fund LP (9.8%, Schedule 13G, filed 2026-05-27); 2 more are listed above.

Who are the largest shareholders of Mentari Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Mentari Therapeutics, Inc. on this page are Vivo Opportunity Fund Holdings, L.P. (21.7%), Fairmount Funds Management LLC (19.99%) and ADAR1 Capital Management, LLC (17.2%).

When did Vivo Opportunity Fund Holdings, L.P. buy into Mentari Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Vivo Opportunity Fund Holdings, L.P. on this page is the Schedule 13D, filed 2026-06-10, reporting 21.7%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Mentari Therapeutics, Inc.

DateRecordFigureOur pageSource
November 10, 2026Leadership change: Gregory Divis appointed, President and Chief Executive Officer, and 1 more—Leadership changesSource
November 6, 2026Acquired Mentari$490MAcquisitionSource

Tools for this story

Each opens in a new tab, filled in for Mentari Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/mentari-therapeutics
Last updated 2026-11-16
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who owns 5% or more of Mentari Therapeutics, Inc.? 7 holders at 5% or more, largest Vivo Opportunity Fund Holdings, L.P. 21.7%. MentionFox, 2026-11-16. https://mentionfox.com/stakes/mentari-therapeutics